E. M. O' Reilly

455 total citations
7 papers, 367 citations indexed

About

E. M. O' Reilly is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, E. M. O' Reilly has authored 7 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Cancer Research and 2 papers in Surgery. Recurrent topics in E. M. O' Reilly's work include Pancreatic and Hepatic Oncology Research (3 papers), Multiple Myeloma Research and Treatments (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). E. M. O' Reilly is often cited by papers focused on Pancreatic and Hepatic Oncology Research (3 papers), Multiple Myeloma Research and Treatments (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). E. M. O' Reilly collaborates with scholars based in United States, Netherlands and Japan. E. M. O' Reilly's co-authors include Ivy Fearen, Linda Sun, Kenneth C. Anderson, Kathleen Colson, David S. Siegel, Laura McBride, Paul G. Richardson, Justin L. Ricker, Syed Rizvi and Judy H. Chiao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

E. M. O' Reilly

7 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. M. O' Reilly United States	6	200	172	122	58	54	7	367
Liya Ma China	11	107 0.5×	93 0.5×	121 1.0×	11 0.2×	22 0.4×	39	305
Jessica C. Petrov United States	13	216 1.1×	242 1.4×	90 0.7×	48 0.8×	43 0.8×	22	476
Nicholas D’Cunha United States	9	85 0.4×	151 0.9×	49 0.4×	17 0.3×	37 0.7×	32	282
T. Sadeghi United States	5	136 0.7×	65 0.4×	237 1.9×	25 0.4×	43 0.8×	11	358
Hejing Huang China	9	101 0.5×	223 1.3×	79 0.6×	20 0.3×	29 0.5×	15	366
Sasan Ghaffari Iran	10	117 0.6×	123 0.7×	40 0.3×	17 0.3×	36 0.7×	21	309
Veit Buecklein Germany	7	68 0.3×	160 0.9×	69 0.6×	36 0.6×	44 0.8×	32	230
Joanna Zawitkowska Poland	11	126 0.6×	115 0.7×	121 1.0×	17 0.3×	32 0.6×	61	386
Kalyani Narra United States	6	101 0.5×	198 1.2×	22 0.2×	19 0.3×	21 0.4×	18	304
Zhongxing Jiang China	13	164 0.8×	118 0.7×	81 0.7×	36 0.6×	19 0.4×	28	364

Countries citing papers authored by E. M. O' Reilly

Since Specialization

Citations

This map shows the geographic impact of E. M. O' Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. M. O' Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. M. O' Reilly more than expected).

Fields of papers citing papers by E. M. O' Reilly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. M. O' Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. M. O' Reilly. The network helps show where E. M. O' Reilly may publish in the future.

Co-authorship network of co-authors of E. M. O' Reilly

This figure shows the co-authorship network connecting the top 25 collaborators of E. M. O' Reilly. A scholar is included among the top collaborators of E. M. O' Reilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. M. O' Reilly. E. M. O' Reilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Janssen, Quisette P., Jacob L. van Dam, Laura R. Prakash, et al.. (2022). FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. JNCI Journal of the National Cancer Institute. 114(5). 695–703. 24 indexed citations

Richardson, Paul G., Constantine Mitsiades, Kathleen Colson, et al.. (2008). Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & lymphoma. 49(3). 502–507. 167 indexed citations

Richardson, Paul G., Constantine S. Mitsiades, Kathleen Colson, et al.. (2007). Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. Blood. 110(11). 1179–1179. 16 indexed citations

Leonard, Gregory D. & E. M. O' Reilly. (2004). Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma. Cancer Treatment Reviews. 30(5). 473–477. 4 indexed citations

Reilly, E. M. O', G.K. Abou-Alfa, W G Harker, et al.. (2004). A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC). Journal of Clinical Oncology. 22(14_suppl). 4006–4006. 53 indexed citations

Reilly, E. M. O', et al.. (2004). A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC). Journal of Clinical Oncology. 22(14_suppl). 4006–4006. 17 indexed citations

Barlogie, Barthel, Peter M. Corry, Laura Lippman, et al.. (1979). Total-body hyperthermia with and without chemotherapy for advanced human neoplasms.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 39(5). 1481–9. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact